In-111-Pentetreotide (OctreoScan)¹¹¹In-pentetreotide

Quick Answer

In-111-pentetreotide (OctreoScan) is the original somatostatin-receptor (SSTR) imaging agent — an octreotide analog conjugated to DTPA and labeled with In-111 — once central to neuroendocrine-tumor localization and the origin of the Krenning score. It has been largely replaced by Ga-68/Cu-64-DOTATATE PET, which offers far higher resolution, sensitivity, quantification, and a single-day protocol. It survives where SSTR-PET is unavailable, but requires delayed, multi-day imaging (In-111's 2.8-day half-life) and misses small lesions the PET agents catch.

Mechanism

The octreotide analog binds SSTR2 (and, with lower affinity, other subtypes) on neuroendocrine tumor cells and is internalized. In-111 decays by electron capture, emitting 171- and 245-keV gammas imaged on a medium-energy collimator — physics that give poorer resolution than the 511-keV coincidence imaging of the PET SSTR agents.

Biodistribution

Physiologic uptake in spleen (highest), kidneys, liver, pituitary, and bowel; renal and hepatobiliary/bowel excretion. Bowel activity confounds abdominal interpretation, mitigated by delayed imaging (± laxative). SPECT/CT improves localization.

Physics

Clinical Indications

• Historic staging and receptor assessment of neuroendocrine tumors.
• Occult-primary localization in metastatic NET.
• Still used where SSTR-PET (DOTATATE) is unavailable; the Krenning score originates here and is applied analogously to DOTATATE PET.

Preparation & Protocol

• Withhold long-acting somatostatin analogs per protocol to avoid receptor blockade.
• Image at 4 and 24 h (± 48 h) — the long half-life mandates delayed, often multi-day imaging.
• SPECT/CT of regions of interest; ensure bowel-activity mitigation for abdominal reads.

Interpretation Highlights

• Grade uptake with the Krenning score (0–4) against liver/spleen — the framework carried forward to DOTATATE PET.
• Splenic/renal/hepatic physiologic uptake is intense; correlate anatomy.
• Sensitivity is lower than SSTR-PET, particularly for small lesions — a negative OctreoScan does not exclude PET-detectable disease.

Reporting Checklist

• State imaging times, SPECT/CT use, and somatostatin-analog hold.
• Report Krenning score for target lesions and reference-organ uptake.
• Caveat lower sensitivity than DOTATATE PET where relevant.

Common Pitfalls

• Lower sensitivity for small lesions than SSTR-PET → missed disease.
• Bowel and renal activity confounding abdominal interpretation.
• Somatostatin-analog blockade falsely reducing uptake.

Board Pearls

In-111-pentetreotide (OctreoScan) is the original SSTR SPECT agent — the octreotide-DTPA study that gave us the Krenning score — now largely replaced by Ga-68/Cu-64-DOTATATE PET, which offers far higher resolution, sensitivity, and quantification in a single-day protocol.

It requires delayed, multi-day imaging (In-111's 2.8-day half-life; imaging at 4 and 24 ± 48 h) and misses small lesions the PET agents catch — so a negative OctreoScan does not exclude PET-detectable disease. Withhold long-acting somatostatin analogs to avoid receptor blockade.

The Krenning score originated here and transfers directly to DOTATATE PET grading. Bowel excretion confounds abdominal reads (delayed/laxative imaging, SPECT/CT help). Its medium-energy 171/245-keV gammas give poorer resolution than 511-keV PET coincidence imaging — the core reason the field moved to Ga-68/Cu-64-DOTATATE.

Related Pages

• Contrast tracer: DOTATATE PET agents (the modern replacement); disease: Neuroendocrine tumors; therapy: ¹⁷⁷Lu-DOTATATE.

Figure / Diagram Suggestions

• An In-111 vs Ga-68 SSTR resolution comparison (SPECT vs PET).
• A Krenning-score origin reference-organ ladder.

Self-Check